Vitiligo Treatment Market Analysis

Type (Segmental Vitiligo, Non-Segmental Vitiligo)

The non-segmental vitiligo segment is predicted to have a significant vitiligo treatment market share during the forecast period of 2025-2037. This dominance is due to the increase in patients diagnosed with non-segmental vitiligo, worldwide. When the skin color starts fading, the most common kind of vitiligo causes skin patches to arise all over the body. Non-segmental vitiligo is generally present when white spots on a person's body are symmetrical apart from asymmetrical. Nevertheless, therapies for non-segmental vitiligo may differ significantly depending on the patient's preferences and the severity of their disease. As a result, the increase in awareness about vitiligo symptoms, causes, and improved treatment alternatives provide lucrative growth opportunities for the segment.

For example, in April 2023, Incyte announced the European Commission (EC) approval of opzelura (ruxolitinib) cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents. Opzelura is the first and only permitted treatment in the European Union (EU) to provide support for repigmentation in eligible patients with non-segmental vitiligo, a chronic autoimmune disease featuring depigmentation of skin and decreased quality of life.

Treatment Type (Topical Treatment, Light Therapy, Surgical Procedures, Others)

Topical treatment segment is anticipated to dominate around 49.5% vitiligo treatment market share by the end of 2037. Topical treatments such as calcineurin inhibitors, corticosteroids, and many new options similar to Janus kinase (JAK) inhibitors are preferred due to their ease of affordability, application, and non-invasive nature. These treatments are mainly effective in managing decreasing inflammation, localized vertigo, and promoting repigmentation while making them a unique choice among patients and healthcare providers.

For instance, according to Vitiligo Research Foundation, in September 2024, Aclaris Therapeutics' lead drug applicant ATI-50002 Topical Solution 0.46% for vitiligo is a JAK1/JAK3 inhibitor. Phase II clinical trials were completed in 2020 with no further development. In January 2024 company declared top-line results from its Phase 2b study of ATI-1777, an investigational topical soft JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis, with an eye for vitiligo down the road.

Our in-depth analysis of the global vitiligo treatment market includes the following segments: